Plus Therapeutics (PSTV) Competitors $1.52 +0.05 (+3.40%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.38 -0.15 (-9.54%) As of 03/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV vs. SURG, PTHL, RVP, VVOS, NXGL, XAIR, LFWD, NEPH, ALUR, and IRIXShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include SurgePays (SURG), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), Retractable Technologies (RVP), Vivos Therapeutics (VVOS), NEXGEL (NXGL), Beyond Air (XAIR), ReWalk Robotics (LFWD), Nephros (NEPH), Allurion Technologies (ALUR), and IRIDEX (IRIX). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. SurgePays Pheton Holdings Ltd Class A Ordinary Shares Retractable Technologies Vivos Therapeutics NEXGEL Beyond Air ReWalk Robotics Nephros Allurion Technologies IRIDEX Plus Therapeutics (NASDAQ:PSTV) and SurgePays (NASDAQ:SURG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings. Which has more volatility & risk, PSTV or SURG? Plus Therapeutics has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, SurgePays has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Does the MarketBeat Community believe in PSTV or SURG? SurgePays received 101 more outperform votes than Plus Therapeutics when rated by MarketBeat users. Likewise, 69.11% of users gave SurgePays an outperform vote while only 62.73% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformPlus TherapeuticsOutperform Votes6962.73% Underperform Votes4137.27% SurgePaysOutperform Votes17069.11% Underperform Votes7630.89% Does the media favor PSTV or SURG? In the previous week, SurgePays had 14 more articles in the media than Plus Therapeutics. MarketBeat recorded 22 mentions for SurgePays and 8 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.22 beat SurgePays' score of 0.12 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SurgePays 3 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in PSTV or SURG? 3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 6.9% of SurgePays shares are owned by institutional investors. 5.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 29.4% of SurgePays shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is PSTV or SURG more profitable? SurgePays has a net margin of -27.39% compared to Plus Therapeutics' net margin of -225.07%. Plus Therapeutics' return on equity of 0.00% beat SurgePays' return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-225.07% N/A -154.56% SurgePays -27.39%-55.63%-43.61% Do analysts recommend PSTV or SURG? Plus Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 689.47%. SurgePays has a consensus target price of $8.50, suggesting a potential upside of 289.91%. Given Plus Therapeutics' higher probable upside, research analysts plainly believe Plus Therapeutics is more favorable than SurgePays.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00SurgePays 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, PSTV or SURG? SurgePays has higher revenue and earnings than Plus Therapeutics. SurgePays is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$4.91M1.83-$13.32M-$2.53-0.60SurgePays$60.88M0.72$20.62M-$2.34-0.93 SummarySurgePays beats Plus Therapeutics on 11 of the 17 factors compared between the two stocks. Remove Ads Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.96M$4.41B$5.64B$8.06BDividend YieldN/A32.65%4.56%4.02%P/E Ratio-0.6028.8624.5919.03Price / Sales1.8349.17383.9393.17Price / CashN/A51.0838.1634.64Price / Book-5.076.146.944.33Net Income-$13.32M$67.64M$3.20B$247.06M7 Day Performance10.14%-1.86%-2.30%-0.53%1 Month Performance125.19%-0.29%3.07%-3.74%1 Year Performance-17.84%15.15%11.15%1.72% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics1.977 of 5 stars$1.52+3.4%$12.00+689.5%-17.8%$8.96M$4.91M-0.6020Short Interest ↑Gap UpHigh Trading VolumeSURGSurgePays3.1243 of 5 stars$1.31-2.2%$8.50+548.9%-41.6%$26.41M$83.60M-1.1640Earnings ReportOptions VolumeAnalyst RevisionNews CoverageGap DownPTHLPheton Holdings Ltd Class A Ordinary SharesN/A$3.91-7.8%N/AN/A$25.74M$572,291.000.0011RVPRetractable TechnologiesN/A$0.75+0.4%N/A-37.3%$22.55M$38.27M-1.39240Analyst ForecastNews CoveragePositive NewsVVOSVivos Therapeutics2.5713 of 5 stars$3.71+3.1%$6.30+69.8%-30.0%$21.85M$14.58M-0.65160Short Interest ↓NXGLNEXGEL0.8938 of 5 stars$3.09+14.4%N/A+14.2%$20.98M$6.73M-5.3310Earnings ReportGap UpXAIRBeyond Air4.5857 of 5 stars$0.28+5.6%$3.67+1,194.3%-83.8%$19.49M$3.02M-0.2770LFWDReWalk Robotics2.4537 of 5 stars$1.80+4.7%$9.00+400.0%-63.7%$19.13M$25.66M-0.7260Short Interest ↑NEPHNephros2.0902 of 5 stars$1.60+2.9%$5.00+213.5%-28.3%$16.82M$14.16M-17.7230Earnings ReportShort Interest ↑ALURAllurion Technologies2.3396 of 5 stars$3.43-4.2%$22.83+565.7%-92.6%$16.44M$34.75M-0.29501Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeIRIXIRIDEX1.2634 of 5 stars$0.95-4.0%$2.00+110.5%-70.1%$15.80M$48.43M-1.42120Earnings ReportAnalyst ForecastHigh Trading Volume Remove Ads Related Companies and Tools Related Companies SurgePays Competitors Pheton Holdings Ltd Class A Ordinary Shares Competitors Retractable Technologies Competitors Vivos Therapeutics Competitors NEXGEL Competitors Beyond Air Competitors ReWalk Robotics Competitors Nephros Competitors Allurion Technologies Competitors IRIDEX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSTV) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
